MedTrace Logo

LaseMD System for the Treatment of Melasma

NCT03456674 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-03-13

No results posted yet for this study

Summary

This study will evaluate the clinical outcomes associated with use of the LaseMD Laser System for the treatment of melasma.

Conditions

  • Melasma

Interventions

DEVICE

LaseMD System

A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.

Sponsors & Collaborators

  • LUTRONIC Corporation

    lead INDUSTRY

Principal Investigators

  • Kari Larson, MBA · Sponsor GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-07
Primary Completion
2019-05-31
Completion
2019-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03456674 on ClinicalTrials.gov